Theranexus (EPA:ALTHX) | Finanzwire

Basculer en Français

8296	Companies
114905	Keywords
55332	Articles
62461	Press releases

Home
Companies
Theranexus

BRIEF

published on 11/19/2024 at 18:05, 1 day 19 hours ago

Theranexus presents positive results for the treatment of Batten disease CLN3

Clinical Trial Theranexus Batten-1 Batten Disease Visual Acuity
PRESS RELEASE

published on 11/19/2024 at 18:00, 1 day 19 hours ago

Update on the Theranexus' Batten-1 project in CLN3 Batten's disease
Theranexus and BBDF present positive results of Batten-1 trial in CLN3 Batten disease patients, showing safety and efficacy of miglustat. Expanded use indicates potential in visual acuity stabilization

Theranexus BBDF Batten-1 Trial CLN3 Batten Disease Miglustat
BRIEF

published on 10/23/2024 at 18:05, 28 days 19 hours ago

Theranexus Announces Its Cash Position as of September 30, 2024

Treasury Batten Disease Miglustat Research Tax Credit Industrial Partnerships
PRESS RELEASE

published on 10/23/2024 at 18:00, 28 days 19 hours ago

THERANEXUS ANNOUNCES ITS CASH POSITION AS OF SEPTEMBER 30, 2024
Theranexus reports €1.9 million cash position as of September 30, 2024, with plans for product registrations and phase 3 trials in rare neurological diseases

Cash Position Biopharmaceutical Theranexus Rare Neurological Diseases Product Registrations
BRIEF

published on 10/17/2024 at 18:05, 1 month 3 days ago

Theranexus partners with Synerlab for a breakthrough in the treatment of Niemann-Pick C

Theranexus EMA Synerlab Miglustat Niemann-Pick C
PRESS RELEASE

published on 10/17/2024 at 18:00, 1 month 3 days ago

THERANEXUS JOINS UP WITH SYNERLAB TO PREPARE THE COMMERCIALIZATION OF ITS PEDIATRIC FORMULATION IN NIEMANN-PICK TYPE C DISEASE
Theranexus partners with Synerlab to produce oral solution of miglustat for Niemann-Pick type C disease, aiming for EMA approval and commercialization by 2026. Novel pediatric formulation Mig-OS provides new therapeutic option for NPC patients

Theranexus Synerlab Miglustat Niemann-Pick Type C Disease EMA Approval
BRIEF

published on 09/26/2024 at 18:05, 1 month 24 days ago

Theranexus announces its financial results for the first half of 2024

Financial Results Cost Reduction Biopharmaceutical Theranexus Batten-1
PRESS RELEASE

published on 09/26/2024 at 18:00, 1 month 24 days ago

THERANEXUS ANNOUNCES FIRST HALF 2024 FINANCIAL RESULTS
Theranexus reports cost reduction success and positive first half 2024 financial results, led by completion of Batten-1 clinical trial and operating grants

Financial Results Cost Reduction Clinical Trial Theranexus Batten-1
BRIEF

published on 07/11/2024 at 18:50, 4 months 9 days ago

Theranexus announces its cash flow as of June 30, 2024 and details the progress of Batten-1

Treasury Funding Theranexus Batten-1 Neurological Disease
PRESS RELEASE

published on 07/11/2024 at 18:45, 4 months 9 days ago

Theranexus publishes its cash position as of 30 June 2024 and presents an update on the progress of Batten-1
Biopharmaceutical company Theranexus announces implementation of new equity line to finance Phase III trial for Batten-1 drug in juvenile Batten disease. Update on Batten-1 program included

Biopharmaceutical Company Phase III Trial Theranexus Batten-1 Equity Line

Accesswire

Published on 11/21/2024 at 13:30, 23 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 23 minutes ago

Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 53 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 53 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 53 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 38 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 18 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 38 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 47 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 53 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 55 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 33 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 8 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 8 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE